Skip to main content

Table 2 Disease-specific characteristics

From: Scleroderma-polymyositis overlap syndrome versus idiopathic polymyositis and systemic sclerosis: a descriptive study on clinical features and myopathology

Characteristics

Number

SSc-overlap (n = 25)

Number

SSc (n = 397)

Number

PM (n = 40)

P value

Scleroderma features

       

Raynaud phenomena

25

21 (84%)

397

379 (96%)

40

13 (33%)

<0.001

Digital ulcers

25

6 (24%)

397

164 (41%)

40

3 (8%)

<0.001

Pitting scars

 

-

397

160 (40%)

 

NA

NA

Rodnan skin score (median)

15

6 (5–11)

372

7 (4–12)

 

NA

NS

Renal crisis

25

1 (4%)

397

17 (4%)

 

NA

NS

Myositis features

       

Serum CK elevation

25

24 (96%)

397

48 (12%)

40

34 (85%)

<0.001

Proximal muscle weakness

25

25 (100%)

397

21 (5%)

40

37 (93%)

<0.001

Myopathic EMG findings

25

22 (88%)

 

NA

29

24 (83%)

NS

Mechanic hands

 

NA

 

NA

40

7 (18%)

NS

Internal complications

       

Arthritis

25

5 (20%)

397

46 (12%)

40

7 (18%)

NS

Interstitial lung disease

       

 HRCT fibrosis

18

15 (83%)

346

170 (49%)

19

10 (53%)

0.044

 TLC ≤70% of predicted

21

4 (19%)

364

68 (19%)

23

9 (39%)

NS

 TLCO ≤70% of predicted

17

17 (100%)

347

260 (75%)

20

13 (65%)

0.001

Diastolic dysfunction by cardiac ultrasound

19

7 (37%)

352

146 (42%)

19

4 (21%)

NS

PH suspicion by cardiac ultrasound

20

3 (15%)

352

89 (25%)

19

2 (11%)

0.042

PH by cardiac catherization

5

0

182

57 (31%)

2

1 (50%)

0.002

Myocarditis

25

1 (4%)

 

NA

40

0

NS

Malignancy

25

2 (8%)

 

NA

40

5 (13%)

NS

  1. NA, not applicable; NS, not significant; TLC, total lung capacity; HRCT, high-resolution CT scan; TLCO, transfer factor of the lung for carbon monoxide; PH, pulmonary hypertension.
  2. Defined >2 times upper limit of normal (ULN).